Gene therapy holds great promise, but the high prevalence of anti-AAV antibodies from prior exposure to non-pathogenic wild-type AAV can significantly impact treatment efficacy, making it necessary to assess the levels of pre-existing AAV immunogenicity antibodies for individual candidates entering clinical trials.
View the recording to learn from Eva-Maria Thüring, Postdoc at Bayer, how to optimize the analysis of pre-existing anti-AAV antibodies in candidates for non-clinical and clinical studies, in human and monkey serum samples, across multiple AAV vector serotypes.
